Premium
Haploidentical transplants for patients with relapse after the first allograft
Author(s) -
Srour Samer A.,
Kongtim Piyanuch,
Rondon Gabriela,
Chen Julianne,
Petropoulos Demetrios,
Ramdial Jeremy,
Popat Uday,
Kebriaei Partow,
Qazilbash Muzaffar,
Shpall Elizabeth J.,
Champlin Richard E.,
Ciurea Stefan O.
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25924
Subject(s) - medicine , interquartile range , transplantation , surgery , hematopoietic stem cell transplantation , oncology
Relapse after allogeneic hematopoietic stem‐cell transplantation (AHSCT) is associated with very poor outcomes. A second transplant offers the possibility of long‐term disease control. We analyzed outcomes with haploidentical donors for second allograft at our institution. All consecutive patients with hematological malignancies ( N = 29) who relapsed after AHSCT and underwent a haploidentical transplant (haploSCT) as second transplant between February 2009 and October 2018 were included. Median age was 36 years (interquartile range (IQR) 24‐60); 83% of patients had high/very high disease risk index; 61% of AML/MDS patients had high‐risk cytogenetics; and only 24% were in complete remission at transplant. With a median follow‐up of 46.9 months, the 3‐year relapse, non‐relapse mortality (NRM), progression‐free survival (PFS) and overall survival (OS) were 30%, 39%, 31% and 40%, respectively. In multivariable analysis (MVA), comorbidity index (HCT‐CI) and detectable donor‐specific anti‐HLA antibodies (DSA) prior to second transplant were significantly associated with worse outcomes. Patients with HCT‐CI <3 and without DSA had 3‐year PFS and OS of 53% and 60.3%, respectively. Our findings suggest that haploSCT as second AHSCT is feasible and potentially curative. Lower HCT‐CI and no DSA were associated with lower NRM and improved survival. Haploidentical grafts might be a preferred donor source for second AHSCT as these are high‐risk patients who frequently need to proceed urgently to transplant.